A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Summary

The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.

Timeline

Start

2022-02-14

Primary completion

2023-02-22

Completion

2023-03-22

Outcome

Met primary endpoint

release “CBL-0202二期臨床試驗第2階段（CBL-0202 Phase 2-Stage 2, NCT04897412 ）最終臨床統計結果，試驗所有主要療效指標與次要療效指標在 ITT與 PP統計族群皆達到臨床與統計上顯著有效意義” caliwaybiopharma.com ↗

Drugs

Indications